Format

Send to

Choose Destination
Cancer. 2011 May 15;117(10):2163-9. doi: 10.1002/cncr.25752. Epub 2010 Nov 18.

Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

Author information

1
Laboratory for Immunological and Molecular Cancer Research, Third Medical Department With Hematology, Medical Oncology, Hemostaseology, Rheumatology, and Infectious Disease of the Private Medical University Hospital of Salzburg, Salzburg, Austria.

Abstract

BACKGROUND:

Early stage chronic lymphocytic leukemia is characterized by a highly variable course of disease. Because it is believed that regulatory T cells (T(regs) ) are potent suppressors of antitumor immunity, the authors hypothesized that increased T(regs) may favor disease progression.

METHODS:

T(reg) levels (cluster of differentiation 3 [CD3]-positive, [CD4]-positive, CD25-positive, and CD127-negative) in peripheral blood from 102 patients were analyzed by flow cytometry. Statistical analysis was used to evaluate correlations with clinical data.

RESULTS:

The relative T(reg) numbers in CD4-positive T cells were significantly greater in patients with chronic lymphocytic leukemia compared with the numbers in a control group of 170 healthy individuals (P = .001). Patients were divided into 2 groups using a median T(reg) value of 9.7% (the percentage of CD4-positive T cells). Patients with higher T(reg) levels had a significantly shorter time to initial treatment (median, 5.9 years) compared with patients who had lower T(reg) levels (median, 11.7 years; log-rank P = .019). Furthermore, T(reg) levels (the percentage of CD4-positive T cells) had significant prognostic power to predict the time to initial treatment in univariate analysis (P = .023) and in multivariate Cox regression analysis that included the variables Rai stage, immunoglobulin heavy-chain variable region gene mutational status, chromosomal aberrations, and CD38 expression (P = .028).

CONCLUSIONS:

Higher T(reg) levels had significant and independent prognostic power for predicting the time to initial treatment in patients with low to intermediate stage chronic lymphocytic leukemia.

PMID:
21523729
DOI:
10.1002/cncr.25752
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center